Complications of myeloma and its treatments

Complications After Surgical Management of Proximal Femoral Metastasis: A Retrospective Study of 417 Patients. Janssen SJ et al. J Am Acad Orthop Surg. 2016 May 25. [Epub ahead of print]. Renal impairment in multiple myeloma: A single center experience. Gorsane I et al. Saudi J Kidney Dis Transpl. 2016 May-Jun;27(3):480-5. doi: 10.4103/1319-2442.182380. A review of the Venous Thrombotic Issues associated with Multiple Myeloma.…

Current treatments

A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma. Becker PS et al. Blood Cancer J. 2016 May 13;6:e422. doi: 10.1038/bcj.2016.31. Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma. Green DJ et al. Bone Marrow Transplant. 2016 May 23. doi: 10.1038/bmt.2016.123. [Epub ahead of…

Diagnostic tests and prognostic indicators

Minimal residual disease monitoring and immune profiling using second generation flow cytometry in elderlymultiple myeloma. Paiva B et al. Blood. 2016 Apr 26. pii: blood-2016-03-705319. [Epub ahead of print]. Development and Validation of Electrochemiluminescence Assays to Measure Free and Total sSLAMF7 in Human Serum in the Absence and Presence of Elotuzumab. Postelnek J et al. AAPS J. 2016 Apr 26. [Epub…

Related conditions

Laboratory testing in monoclonal gammopathy of renal significance (MGRS). Leung N et al. Clin Chem Lab Med. 2016 Apr 23. pii: /j/cclm.ahead-of-print/cclm-2015-0994/cclm-2015-0994.xml. doi: 10.1515/cclm-2015-0994. [Epub ahead of print]. Can We Cure Light Chain Deposition Disease of the Kidneys?-A Review and Case Report of a Patient Treated With a Triple Transplant Approach. Sivaraj D et al. Clin Lymphoma Myeloma Leuk. 2016 Mar 29. pii:…

Emerging treatments

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. Moreau P et al. N Engl J Med. 2016 Apr 28;374(17):1621-1634. Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractorymultiple myeloma: dose selection for a phase 3 maintenance study. Gupta N et al. Invest New Drugs. 2016 Apr 2. [Epub ahead of print]. Phase 1 Clinical Trial of Marizomib (NPI-0052) in Patients…

Biology and genetics

Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease. Fu J et al. J Clin Invest. 2016 Apr 4. pii: 80276. doi: 10.1172/JCI80276. [Epub ahead of print]. Abnormal IGF-Binding Protein Profile in the Bone Marrow of Multiple Myeloma Patients. Bieghs L et al. PLoS One. 2016 Apr 25;11(4):e0154256. doi: 10.1371/journal.pone.0154256. eCollection 2016. Assessment of tumoral plasma cells in apheresis products for autologous stem…

General

Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma. Martino M et al. Bone Marrow Transplant. 2016 Apr 4. doi: 10.1038/bmt.2016.79. [Epub ahead of print]. Nuances in the Management of Older People With Multiple Myeloma. Pawlyn C et al. Curr Hematol Malig Rep. 2016 Apr 2. [Epub ahead of print]. Management of multiple myeloma in older adults: Gaining ground with…